Coronary Artery Disease Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Coronary artery disease (CAD) — also called ischaemic heart disease — is the most prevalent form of cardiovascular disease, caused by atherosclerosis: the progressive build-up of cholesterol-rich plaques within the walls of the coronary arteries that supply blood to the heart muscle. As these plaques accumulate, the arterial lumen narrows, reducing blood flow to the myocardium and causing ischaemia — an imbalance between myocardial oxygen supply and demand manifesting as chest pain (angina), breathlessness, or silent ischaemia. Acute plaque rupture triggers thrombus formation, producing acute coronary syndromes (unstable angina, NSTEMI, STEMI — heart attack).

CAD is responsible for approximately 9 million deaths annually worldwide, making it the single most lethal condition in both men and women. In the United States, someone suffers a myocardial infarction every 40 seconds. The prevalence of CAD increases dramatically with age (affecting over 20% of men above age 65) and is substantially higher in patients with diabetes, hypertension, hypercholesterolaemia, smoking history, obesity, and family history of premature cardiovascular disease (first-degree relative with CAD before age 55 in men or 65 in women).

The treatment of CAD is guided by the clinical presentation (stable CAD versus acute coronary syndrome), the extent and anatomical complexity of coronary disease, left ventricular function, the presence of ischaemia on non-invasive or invasive assessment, and patient characteristics and preferences. The cornerstone of management is risk factor modification and guideline-directed medical therapy, which reduces future cardiac events regardless of whether revascularisation is performed.

Stable angina — predictable, exertion-related chest pain that resolves with rest or nitrates — is the chronic presentation of obstructive CAD. It is treated with anti-ischaemic medications (beta-blockers, long-acting nitrates, ivabradine, ranolazine, nicorandil) to reduce angina frequency and improve exercise tolerance, plus coronary revascularisation (PCI or CABG) when symptoms are refractory or when prognostically significant disease is identified. Unstable angina and NSTEMI — acute coronary syndromes with ECG changes and elevated troponin — require hospitalisation, antiplatelet and anticoagulant therapy, and early invasive coronary angiography with revascularisation.

ST-elevation myocardial infarction (STEMI) — complete acute coronary occlusion — is a cardiac emergency requiring immediate activation of the cardiac catheterisation laboratory for primary PCI within 90 minutes. Silent ischaemia — haemodynamically significant CAD without symptoms, detected on stress testing or coronary imaging — requires the same systematic risk factor management as symptomatic CAD. Microvascular angina (previously syndrome X) — chest pain with normal coronary arteries on angiography but evidence of coronary microvascular dysfunction — requires treatment of the microvascular dysfunction with endothelin antagonists, ranolazine, or other agents targeting coronary microvascular resistance.

All patients with documented obstructive CAD — by coronary angiography, CT coronary angiography, or positive non-invasive ischaemia testing — are candidates for guideline-directed medical therapy and risk factor management. The decision to proceed to coronary revascularisation is based on the presence of haemodynamically significant stenoses (proven by FFR, iFR, or objective ischaemia testing), symptom burden despite optimal medical therapy, and anatomical suitability for PCI or CABG.

Primary prevention — treatment of cardiovascular risk factors in patients without established CAD — is appropriate for all individuals with a calculated 10-year cardiovascular risk above 7.5% (ACC/AHA threshold) or above 10% (ESC/SCORE2 threshold), or with high-risk features such as LDL above 4.9 mmol/L, hypertension with target organ damage, or diabetes with microalbuminuria. Aspirin is no longer recommended for primary prevention in patients without established cardiovascular disease due to the unfavourable bleeding-to-benefit ratio in lower-risk individuals.

Medical therapy is the foundation of CAD management and includes antiplatelet therapy (aspirin 75–100 mg daily, supplemented by a P2Y12 inhibitor for 12 months after ACS or PCI; rivaroxaban 2.5 mg twice daily as an addition to aspirin in stable CAD with high ischaemic risk and low bleeding risk from the COMPASS trial), high-intensity statins (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) to achieve LDL below 1.4 mmol/L, PCSK9 inhibitors (evolocumab, alirocumab) for patients not achieving LDL targets on maximum statin therapy, ACE inhibitors (all patients with LVEF below 40% post-MI, and those with hypertension or diabetes), and anti-anginal agents (beta-blockers first-line, with nitrates, ivabradine, ranolazine, amlodipine, and nicorandil as add-on or alternatives).

Coronary revascularisation with PCI or CABG restores blood flow to ischaemic myocardium. PCI is preferred for single-vessel and simple multi-vessel disease; CABG provides superior long-term outcomes for three-vessel disease, left main disease, and multi-vessel CAD in diabetics. Cardiac rehabilitation after any coronary event or revascularisation reduces mortality by 20–26% and should be offered to all eligible patients. Colchicine 0.5 mg daily — an anti-inflammatory drug — reduces recurrent cardiovascular events in stable CAD and after myocardial infarction (COLCOT trial), reflecting the role of residual inflammatory risk in atherosclerosis progression.

The cumulative effect of modern CAD management — combining aggressive risk factor modification with evidence-based pharmacotherapy and timely revascularisation — has achieved dramatic reductions in cardiovascular mortality over the past five decades. Since the 1970s, age-standardised coronary heart disease mortality has fallen by over 50% in most high-income countries, reflecting both improved acute treatment (thrombolysis, then primary PCI) and secondary prevention (statins, dual antiplatelet therapy, ACE inhibitors, cardiac rehabilitation).

For individual patients, each therapeutic intervention contributes meaningfully: statin therapy reduces major cardiovascular events by 22% per mmol/L LDL reduction; adding ezetimibe to statins reduces events by a further 6–7%; PCSK9 inhibitors added to maximally tolerated statin therapy reduce LDL by 50–60% and cardiovascular events by 15%. Dual antiplatelet therapy after ACS reduces recurrent MI and stent thrombosis by 20–30%. Colchicine added to standard therapy after MI reduces cardiovascular events by 23% at 2 years (COLCOT trial). Complete coronary revascularisation before elective major non-cardiac surgery reduces perioperative cardiovascular complications in patients with significant unstable CAD.

CAD itself carries the highest risk of myocardial infarction and cardiovascular death. Acute MI — particularly large anterior STEMI — can cause life-threatening arrhythmias (ventricular fibrillation), cardiogenic shock, mechanical complications (ventricular septal defect, papillary muscle rupture, free wall rupture), and acute heart failure. Even with successful reperfusion, myocardial scar after MI may predispose to ventricular tachyarrhythmias and heart failure over the long term.

Treatment-related risks include bleeding from antiplatelet and anticoagulant therapy (major bleeding 1–3% per year), statin myopathy (clinically significant myositis less than 0.1%), ACE inhibitor-induced hypotension and renal impairment (particularly in volume-depleted or bilateral renal artery stenosis), and procedural risks of coronary angiography and revascularisation as described in respective sections. Nitrate tolerance develops with continuous nitrate use and is mitigated by a 10–12 hour nitrate-free period daily. Cardiovascular risk remains elevated even after successful revascularisation and medical therapy optimisation, requiring lifelong surveillance and continued secondary prevention.

After acute coronary syndrome, follow-up at 4–6 weeks assesses symptom recovery, medication tolerability, and cardiac rehabilitation enrolment. Serial echocardiography at 6–12 weeks after STEMI documents LVEF recovery and guides ICD consideration (implantation deferred for 40 days after MI in patients with persistent LVEF below 35%). Annual review thereafter includes clinical assessment, ECG, HbA1c and lipid profile, and blood pressure measurement, targeting LDL below 1.4 mmol/L, blood pressure below 130/80 mmHg, HbA1c below 53 mmol/mol, and weight management.

For patients with stable chronic CAD, stress testing may be performed every 2–3 years or when new or worsening symptoms develop. CT coronary angiography or repeat invasive coronary angiography is performed when clinical symptoms or objective testing suggest progression of disease or stent restenosis. Long-term dual antiplatelet therapy (aspirin plus low-dose rivaroxaban) may be continued beyond 12 months in stable high-ischaemic-risk, low-bleeding-risk patients based on COMPASS trial data.

Annual costs of CAD management in the United States include medications ($3,000–$8,000 including branded PCSK9 inhibitors), specialist visits and investigations ($2,000–$5,000), and any revascularisation procedures ($20,000–$200,000 depending on intervention type). Total lifetime CAD management costs in the US routinely exceed $200,000–$500,000. In the UK, NHS CAD care is provided free at point of care, though waiting times for elective procedures can be months.

For medical tourists, comprehensive CAD management — including diagnostic coronary angiography, PCI or CABG revascularisation, and establishment of a long-term medical management plan — is available at JCI-accredited cardiac centres in India (Fortis Escorts Heart Institute, Apollo, Narayana, Medanta), Thailand (Bumrungrad, Bangkok Heart Hospital), Turkey (Acibadem), and Singapore at 60–80% lower cost than in the United States. PCSK9 inhibitors are available at lower cost in India, Turkey, and Eastern Europe. For patients managing chronic stable CAD at lower cost, annual review, echocardiography, and medication review in India costs $500–$1,500 versus $3,000–$8,000 in the US.

The ISCHEMIA trial challenged the assumption that routine revascularisation improves outcomes over optimal medical therapy in all patients with stable CAD and significant ischaemia, demonstrating equivalent rates of cardiovascular death and MI between an initial conservative (medical therapy) and invasive (angiography with revascularisation) strategy over a median 3.2-year follow-up, though PCI provided better angina relief. This landmark finding has reinforced medical therapy as the appropriate first-line approach for stable, adequately symptomatic CAD patients.

Complementary approaches for secondary prevention include the Mediterranean diet (30% relative risk reduction vs low-fat diet in PREDIMED trial), high-intensity aerobic exercise (equivalent to medication in some studies for reducing cardiovascular events), omega-3 fatty acids at prescription doses (icosapentaenoic acid 4g/day — REDUCE-IT trial: 25% reduction in cardiovascular events), and stress reduction through mindfulness and cardiac psychology programmes. Ranolazine (a late sodium channel blocker) and ivabradine (an If channel inhibitor reducing heart rate without blood pressure effect) provide additional anti-ischaemic therapy for patients not achieving adequate symptom control on standard agents.